TY - JOUR
T1 - Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation
AU - Locatelli, Franco
AU - Vinti, Luciana
AU - Palumbo, Giuseppe
AU - Rossi, Francesca
AU - Bertaina, Alice
AU - Mastronuzzi, Angela
AU - Bernardo, Maria Ester
AU - Rutella, Sergio
AU - Dellabona, Paolo
AU - Giorgiani, Giovanna
AU - Moretta, Alessandro
AU - Moretta, Lorenzo
PY - 2011
Y1 - 2011
N2 - The most advanced frontier of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is represented by the use of an HLA-partially matched relative as donor. In this type of transplantation, donor-derived natural killer (NK) cells, which are alloreactive towardtoward recipient cells, significantly contribute to the eradication of leukemia blasts. Alloreactive NK cells may also kill host dendritic cells and T lymphocytes, thus preventing graft-versus-host disease and graft rejection, respectively. Sophisticated strategies of adoptive infusion of T-cell lines/clones specific for the most life-threatening pathogens (namely cytomegalovirus, Epstein-Barr virus, Aspergillus and Adenovirus) have been envisaged, and successfully tested in a few pilot trials, to protect the recipient in the early post-transplantation period. In these patients, also ex-vivo expanded mesenchymal stromal cells have been shown to be beneficial for preventing graft failure. Novel and effective strategies aimed at further augmenting the graft-versus-leukemia effect and at optimizing prevention/treatment of opportunistic/viral infections are warranted. (C) 2011 Elsevier Ltd. All rights reserved.
AB - The most advanced frontier of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is represented by the use of an HLA-partially matched relative as donor. In this type of transplantation, donor-derived natural killer (NK) cells, which are alloreactive towardtoward recipient cells, significantly contribute to the eradication of leukemia blasts. Alloreactive NK cells may also kill host dendritic cells and T lymphocytes, thus preventing graft-versus-host disease and graft rejection, respectively. Sophisticated strategies of adoptive infusion of T-cell lines/clones specific for the most life-threatening pathogens (namely cytomegalovirus, Epstein-Barr virus, Aspergillus and Adenovirus) have been envisaged, and successfully tested in a few pilot trials, to protect the recipient in the early post-transplantation period. In these patients, also ex-vivo expanded mesenchymal stromal cells have been shown to be beneficial for preventing graft failure. Novel and effective strategies aimed at further augmenting the graft-versus-leukemia effect and at optimizing prevention/treatment of opportunistic/viral infections are warranted. (C) 2011 Elsevier Ltd. All rights reserved.
KW - NK alloreactivity
KW - cellular therapy
KW - graft-versus-leukemia effect
KW - invariant NKT cells
KW - mesenchymal stromal cells
KW - pathogen-specific T cells
KW - NK alloreactivity
KW - cellular therapy
KW - graft-versus-leukemia effect
KW - invariant NKT cells
KW - mesenchymal stromal cells
KW - pathogen-specific T cells
UR - https://publicatt.unicatt.it/handle/10807/249194
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=80053024772&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80053024772&origin=inward
U2 - 10.1016/j.beha.2011.04.004
DO - 10.1016/j.beha.2011.04.004
M3 - Article
SN - 1521-6926
VL - 24
SP - 339
EP - 349
JO - BAILLIERE'S BEST PRACTICE IN CLINICAL HAEMATOLOGY
JF - BAILLIERE'S BEST PRACTICE IN CLINICAL HAEMATOLOGY
IS - 3
ER -